Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kramer

Showing results (231-240 of 240) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 240 results.
Annals of Epidemiology|January 19, 2026
Residential Mobility During Pregnancy and Birth Outcomes in the United States: The Environmental influences on Child Health Outcomes (ECHO) Cohort (2010-2019)Angela D'Adamo, Amii M Kress, Rima Habre, et al.
American Journal of Hematology|October 2, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialKatja Sockel, Christoph Röllig, Anke Mütherig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2019
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International CohortsLinus Angenendt, Christoph Röllig, Pau Montesinos, et al.
Nature Communications|November 12, 2022
Deep phenotyping and lifetime trajectories reveal limited effects of longevity regulators on the aging process in C57BL/6J miceKan Xie, Helmut Fuchs, Enzo Scifo, et al.
Science Advances|March 6, 2018
Einstein@Home discovers a radio-quiet gamma-ray millisecond pulsarColin J Clark, Holger J Pletsch, Jason Wu, et al.
Physical Review Letters|October 16, 2020
Gravitational Test beyond the First Post-Newtonian Order with the Shadow of the M87 Black HoleDimitrios Psaltis, Lia Medeiros, Pierre Christian, et al.
Pageof 24

Showing results (231-240 of 240) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 240 results.
Annals of Epidemiology|January 19, 2026
Residential Mobility During Pregnancy and Birth Outcomes in the United States: The Environmental influences on Child Health Outcomes (ECHO) Cohort (2010-2019)Angela D'Adamo, Amii M Kress, Rima Habre, et al.
American Journal of Hematology|October 2, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialKatja Sockel, Christoph Röllig, Anke Mütherig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2019
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International CohortsLinus Angenendt, Christoph Röllig, Pau Montesinos, et al.
Nature Communications|November 12, 2022
Deep phenotyping and lifetime trajectories reveal limited effects of longevity regulators on the aging process in C57BL/6J miceKan Xie, Helmut Fuchs, Enzo Scifo, et al.
Science Advances|March 6, 2018
Einstein@Home discovers a radio-quiet gamma-ray millisecond pulsarColin J Clark, Holger J Pletsch, Jason Wu, et al.
Physical Review Letters|October 16, 2020
Gravitational Test beyond the First Post-Newtonian Order with the Shadow of the M87 Black HoleDimitrios Psaltis, Lia Medeiros, Pierre Christian, et al.
Pageof 24